Methadone, QTc interval prolongation and torsade de pointes: CasE reports offer the best understanding of this problem

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 4, 2013, Pages 219-232

  Vieweg, W Victor R ^a   Hasnain, Mehrul ^b   Howland, Robert H ^c   Clausen, Thomas ^d   Koneru, Jayanthi N ^e   Kogut, Christopher ^e   Crouse, Ericka L Breden ^a   Hancox, Jules C ^f   Fernandez, Antony ^a   Pandurangi, Ananda K ^e  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Drug induced QTc interval prolongation; methadone; risk factors; torsade de pointes

Indexed keywords

METHADONE; POTASSIUM CHANNEL HERG;

ADULT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; MALE; PRIORITY JOURNAL; QT DISPERSION; QT PROLONGATION; REVIEW; SEX DIFFERENCE; SINUS BRADYCARDIA; TORSADE DES POINTES;

EID: 84997906136     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312469982     Document Type: Article

References (82)

1. Abramson D.W. Quinn D.K. Stern T.A. (2008) Methadone-associated QTc prolongation: a case report and review of the literature. Prim Care Comp J Clin Psychiatry 10: 470–476.
2. Agus Z.S. (1999) Hypomagnesemia. J Am Soc Nephrol 10: 1616–1622.
3. Almehmi A. Malas A.M. Yousufuddin M. Rosencrance J.G. (2004) Methadone-induced torsade de pointes in a patient with normal baseline QT interval. West Virginia M J 100: 147–148.
4. Anchersen K. Clausen T. Gossop M. Hansteen V. Waal H. (2009) Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 104: 993–999.
5. Anchersen K. Hansteen V. Gossop M. Clausen T. Waal H. (2010) Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. Drug Alcohol Depend 112: 216–219.
6. Anderson I.B. Kearney T.E. (2000) Use of methadone. Western J Med 172: 43–46.
7. Ansermot N. Albayrak O. Schlapfer J. Crettol S. Croquette-Krokar M. Bourquin M. et al. (2010) Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med 170: 529–536.
8. Arbel Y. Swartzon M. Justo D. (2007) QT Prolongation and torsades de pointes in patients previously treated with anthracyclines. Anti-Cancer Drugs 18: 493–498.
9. Backmund M. Schutz C.G. Meyer K. Eichenlaub D. Soyka M. (2003) Alcohol consumption in heroin users, methadone-substituted and codeine-substituted patients–frequency and correlates of use. Eur Addiction Res 9: 45–50.
10. Bednar M.M. Harrigan E.P. Anziano R.J. Camm A.J. Ruskin J.N. (2001) The QT interval. Prog Cardiovasc Dis 43 (5 Suppl 1): 1–45.
11. Brachmann J. Scherlag B.J. Rosenshtraukh L.V. Lazzara R. (1983) Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 68: 846–856.
12. Calver L. Dunlop A.J. Isbister G.K. (2012) Individual patient assessment of methadone-induced QT prolongation with digital holter recording. J Addiction Med 6: 92–93.
13. Chang K.-C. Huang C.-L. Liang H.-Y. Chang S.-S. Wang Y.-C. Liang W.-M. et al. (2011) Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. J Cardiovasc Electrophysiol 23: 527–533.
14. Chugh S.S. Socoteanu C. Reinier K. Waltz J. Jui J. Gunson K. (2008) A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 121: 66–71.
15. Crotti L. Hu D. Barajas-Martinez H. De Ferrari G.M. Oliva A. Insolia R. et al. (2012) Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm 9: 1104–1112.
16. Cruciani R.A. (2008) Methadone: To ECG or not to ECG…that is still the question. J Pain Symptom Manage 36: 545–552.
17. De Jong I.M. De Ruiter G.S. (2011) Buprenorphine as a safe alternative to methadone in a patient with acquired long QT syndrome: a case report. Netherlands Heart J Ahead of print 29 January 2011
18. Deamer R.L. Wilson D.R. Clark D.S. Prichard J.G. (2001) Torsades de pointes associated with high dose levomethadyl acetate (Orlaam®). J Addictive Dis 20: 7–15.
19. Department of Health (England) and the Devolved Administrations. (2007) Drug Misuse and Dependence: Uk Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive.
20. Drug and Alcohol Services Information System. (2006 http://www.oas.samhsa.gov/2k6/otp/otp.htm) Facilities operating opioid treatment programs: 2005, The DASIS Report, Vol. 36.
21. Eap C.B. Crettol S. Rougier J.S. Schlapfer J. Sintra Grilo L. Deglon J.J. et al. (2007) Stereoselective block of herg channel by (s)-methadone and QT interval prolongation in Cyp2b6 slow metabolizers. Clin Pharmacol Ther 81: 719–728.
22. Esses J.L. Rosman J. Do L.T. Schweitzer P. Hanon S. (2008) Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes. J Interventional Cardiac Electrophysiol 23: 117–119.
23. Falconer M. Molloy D. Ingerhaug J. Barry M. (2007) Methadone induced torsade de pointes in a patient receiving antiretroviral therapy. Irish Med J 100: 631–632.
24. Gil M. Sala M. Anguera I. Chapinal O. Cervantes M. Guma J.R. et al. (2003) QT Prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 92: 995–997.
25. Gintant G.A. (2008) Preclinical torsades-de-pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 119: 199–209.
26. Gleick J. (1987) Chaos: making a new science. Viking: New York.
27. Hancox J.C. McPate M.J. El Harchi A. Zhang Y.H. (2008) The Herg potassium channel and Herg screening for drug-induced torsades de pointes. Pharmacol Ther 119: 118–132.
28. Hanon S. Seewald R.M. Yang F. Schweitzer P. Rosman J. (2010) Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interventional Cardiac Electrophysiol 28: 19–22.
29. Hussain T. Ewer A.K. (2007) Maternal methadone may cause arrhythmias in neonates. Acta Paediatrica 96: 768–769.
30. Iskandar S.B. Abi-Saleh B.S. Mechleb B.K. Fahrig S.A. (2007) Methadone and torsade de pointes: case report and review of the literature. Tennessee Med 100: 35–42.
31. John J. Amley X. Bombino G. Gitelis C. Topi B. Hollander G. et al. (2010) Torsade de pointes due to methadone use in a patient with hiv and hepatitis C coinfection. Cardiol Res Practice 2010: 524764.
32. Kang J. Chen X.L. Wang H. Rampe D. (2003) Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channels. Eur J Pharmacol 458: 25–29.
33. Katchman A.N. Koerner J. Tosaka T. Woosley R.L. Ebert S.N. (2006) Comparative evaluation of herg currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 316: 1098–1106.
34. Katchman A.N. McGroary K.A. Kilborn M.J. Kornick C.A. Manfredi P.L. Woosley R.L. et al. (2002) Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 303: 688–694.
35. Kornick C.A. Kilborn M.J. Santiago-Palma J. Schulman G. Thaler H.T. Keefe D.L. et al. (2003) QTc interval prolongation associated with intravenous methadone. Pain 105: 499–506.
36. Krantz M.J. Garcia J.A. Mehler P.S. (2005) Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacother 25: 611–614.
37. Krantz M.J. Kutinsky I.B. Robertson A.D. Mehler P.S. (2003) Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes Pharmacother 23: 802–805.
38. Krantz M.J. Lewkowiez L. Hays H. Woodroffe M.A. Robertson A.D. Mehler P.S. (2002) Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137: 501–504.
39. Krantz M.J. Lowery C.M. Martell B.A. Gourevitch M.N. Arnsten J.H. (2005) Effects of methadone on Qt-interval dispersion. Pharmacother 25: 1523–1529.
40. Krantz M.J. Rowan S.B. Mehler P.S. (2005) Cocaine-related torsade de pointes in a methadone maintenance patient. J Addictive Dis 24: 53–60.
41. Kuryshev Y.A. Bruening-Wright A. Brown A.M. Kirsch G.E. (2010) Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels. J Cardiovasc Pharmacol 56: 420–430.
42. Lin C. Somberg T. Molnar J. Somberg J. (2009) The effects of chiral isolates of methadone on the cardiac potassium channel Ikr. Cardiology 113: 59–65.
43. Lüthi B. Huttner A. Speck R.F. Mueller N.J. (2007) Methadone-induced torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis 26: 367–369.
44. Magnano A.R. Talathoti N.B. Hallur R. Jurus D.T. Dizon J. Holleran S. et al. (2006) Effect of acute cocaine administration on the QTc interval of habitual users. Am J Cardiol 97: 1244–1246.
45. Makkar R.R. Fromm B.S. Steinman R.T. Meissner M.D. Lehmann M.H. (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. J Am Med Assoc 270: 2590–2597.
46. Mantelli L. Corti V. Bini R. Cerbai E. Ledda F. (1986) [Effects of Dl-methadone on the response to physiological transmitters and on several functional parameters of the isolated guinea-pig heart]. Archives Internationales de Pharmacodynamie et de Therapie 282: 298–313.
47. Maremmani I. Pacini M. Cesaroni C. Lovrecic M. Perugi G. Tagliamonte A. (2005) QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addiction Res 11: 44–49.
48. Martell B.A. Arnsten J.H. Krantz M.J. Gourevitch M.N. (2005) Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 95: 915–918.
49. Miceli J.J. Tensfeldt T.G. Shiovitz T. Anziano R. O'gorman C. Harrigan R.H. (2010) Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacother: J Hum Pharmacol Drug Ther 30: 127–135.
50. Nair M.K. Patel K. Starer P.J. (2008) Ciprofloxacin-Induced torsades de pointes in a methadone-dependent patient. Addiction 103: 2062–2064.
51. Noorzurani M.H. Vicknasingam B. Narayanan S. (2009) Itraconazole-induced torsade de pointes in a patient receiving methadone substitution therapy. Drug Alcohol Rev 28: 688–690.
52. Nordt S.P. Zilberstein J. Gold B. (2011) Methadone-induced torsade de pointes. Am J Emergency Med 29: 476.e471–476.e472.
53. Pimentel L. Mayo D. (2008) Chronic methadone therapy complicated by torsades de pointes: a case report. J Emergency Med 34: 287–290.
54. Prosser J.M. Mills A. Rhim E.S. Perrone J. (2008) Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emergency Med 1: 217–220.
55. Puri R. Roberts-Thomson K.C. Young G.D. (2009) HIV and long QT syndrome—cause or coincidence. Int J Cardiol 133: e9–e10.
56. Raschi E. Ceccarini L. De Ponti F. Recanatini M. (2009) Herg-related drug toxicity and models for predicting herg liability and QT prolongation. Exp Opin Drug Metab Toxicol 5: 1005–1021.
57. Redfern W.S. Carlsson L. Davis A.S. Lynch W.G. Mackenzie I. Palethrope S. (2003) Relationship between preclinical electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug devleopment. Cardiovasc Res 58: 32–45.
58. Reinhold J.A. Sanoski C.A. Russo A.M. Cooper J.M. Spinler S.A. (2009) Torsades de pointes associated with methadone and voriconazole. Br Med J Case Reports Epub 2009 December 22
59. Routhier D.D. Katz K.D. Brooks D.E. (2007) QTc prolongation and torsades de pointes associated with methadone therapy. J Emergency Med 32: 275–278.
60. Roxane Laboratories. (2003) Dolphine hydrochloride (methadone hydrochloride tablets) package insert.
61. Roy A.K. McCarthy C. Kiernan G. McGorrian C. Keenan E. Mahon N.G. et al. (2012) Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. Addiction 107: 1132–1139.
62. Sanguinetti M.C. Jiang C. Curran M.E. Keating M.T. (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: herg encodes the Ikr potassium channel. Cell 81: 299–307.
63. Sanguinetti M.C. Mitcheson J.S. (2005) Predicting drug-Herg channel interactions that cause acquired long QT syndrome. Trend Pharmacol Sci 26: 119–124.
64. Sekine R. Obbens E.M.T. Coyle N. Inturrisi C.E. (2007) The successful use of parenteral methadone in a patient with a prolonged QTc interval. J Pain Symptom Manage 34: 566–569.
65. Sticherling C. Schaer B.A. Ammann P. Maeder M. Osswald S. (2005) Methadone-induced torsade de pointes tachycardias. Swiss Medical Weekly 135: 282–285.
66. Taleb N.N. (2010) The black swan, 2nd Edition. Random House: New York.
67. Thanavaro K.L. Thanavaro J.L. (2011) Methadone–induced torsades de pointes: a twist of fate. Heart Lung: J Acute Crit Care 40: 448–453.
68. Trudeau M.C. Warmke J.W. Ganetzky B. Robertson G.A. (1995) Herg, a human inward rectifier in the voltage-gated potassium channel family. Science 269: 92–95.
69. Vieweg W.V. Hasnain M. Howland R.H. Hettema J.M. Kogut C. Wood M.A. et al. (2012) Citalopram, QTc interval prolongation and torsade de pointes. how should we apply the recent FDA ruling? Am J Med 125: 859–868.
70. Vieweg W.V.R. (2003) New generation antipsychotic drugs and QTc interval prolongation. Prim Care Comp J Clin Psychiatry 5: 205–215.
71. Vieweg W.V.R. Hasnain M. Wood M.A. Fernandez A. Lesnefsky E.J. Pandurangi A.K. (2011) Cardiometabolic risks of antidepressant and antipsychotic drugs, part 1. proarrhythmic risks of antidepressant and antipsychotic drugs. Psychiatric Times 28 (April): 50–55.
72. Vieweg W.V.R. Schneider R.K. Wood M.A. (2005) Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatrica Scandinavica 112: 319–323.
73. Vieweg W.V.R. Wood M.A. (2004) Tricyclic antidepressants, QT interval prolongation and torsade de pointes Psychosomatics 45: 371–377.
74. Vieweg W.V.R. Wood M.A. Fernandez A. Beatty-Brooks M. Hasnain M. Pandurangi A.K. (2009) Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26: 997–1012.
75. Viskin S. Justo D. Halkin A. Zeltser D. (2003) Long QT syndrome caused by noncardiac drugs. Progress in Cardiovascular Diseases 45: 415–427.
76. Vodoz J.F. Jaquier F. Lamy O. (2003) Torsade de pointes: a severe and unknown adverse effect in a patient taking methadone. Praxis (Bern 1994) 92: 1748–1750.
77. Walker P.W. Klein D. Kasza L. (2003) High dose methadone and ventricular arrhythmias: a report of three cases. Pain 103: 321–324.
78. Witchel H.J. Hancox J.C. (2000) Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 27: 753–766.
79. Wong S. Roberts J. (2007) Case files of the drexel university medical toxicology fellowship: methadone-induced QTc prolongation. J Med Toxicol 3: 190–194.
80. Zeltser D. Justo D. Halkin A. Prokhorov V. Heller K. Viskin S. (2003) Torsade de pointes due to noncardiac drugs. most patients have easily identifiable risk factors. Medicine 82: 282–290.
81. Zickler P. (2000) Gender differences in prevalence of drug abuse traced to opportunities to use. NIDA Notes 15 Number 4: 1–2.
82. Zunkler B.J. Wos-Maganga M. (2010) Comparison of the effects of methadone and heroin on Human ether-a-go-go-related gene channels. Cardiovasc Toxicol 10: 161–165.